About m3datek

M3DATEK Srl bioprinting activity centers around the development of 3D-bioprinters, key structures and compositional materials targeting tissue repair and tissue regeneration.
The activity of the M3DATEK group is based on the development of medical devices based on new materials (bio-inks), like stimuli-sensitive bio compatible and bioresorbable polymers. Then the bio-ink is dispensed from a bioprinter in a layer-by-layer approach to build finely tuned scaffolds in a variety of advanced designs, presenting significantly improved cell-compatibility.
M3datek’s bioprinter platform is continuously under development through the creation of highly reproducible, robust and flexible instruments. M3datek’s bioprinters are developed for use in tissue repair and regeneration.
The M3DATEK staff is the combination of highly qualified and enthusiastic of technical engineers, chemists, pharmaceutical technologists and biotechnologists.
At M3DATEK, all operation, material developing tests, printing processes, cell-based assays and experimental model (in vivo tests) are executed understanding the importance of scientific method and coordinated by experienced staff, to investigate the tissue repair and tissue regeneration properties of the developed products.
In the Quality Assurance area, under the supervision of an experienced team, the printing process, the product development process, the in-vitro and in-vivo tests follow strict standardized protocols to ensure quality and reproducibility.
If you are interested in developing a product or an assay with M3DATEK and you would like to visit our facility, please contact us to arrange for a tour of our facility in Parma, Italy.



Chief Tecnology Officer (CTO) & co-Founder

Marco Silvestri worked in automation and industrial vision fields as developer and responsible for validating automated machinery for GSK (ampoules) and BBraun (medical devices). He’s been head of R&D of the equipment manufacturer for meat industry Tecnomec srl.

Since 2002 he is researcher at University of Parma, where he’s been scientific manager of the postgraduate course on Automated Machines for the Life Sciences Industries. Since 2012 he is docent-researcher at the University of Applied Science of Southern Switzerland.

He is chief scientist of several research and technology transfer projects in the fields of 3D printing of food and biomedical products, in-line metrology for high precision manufacturing, advanced diagnostic systems and non-conventional controls for homogenizers. He’s been active member of GAMP Italy since its foundation (2006).


Biopharmaceutical Chief Operating Officier (COO) & co-Founder 

Annalisa Bianchera, after her master degree in Health Biotechnology, developed a cross expertise in biotech and pharmaceutical technologies. During her PhD course in Biology and Molecular Pathology she focused on the isolation of multipotent stem cells for tissue regeneration, acquiring a sound know-how in the setting up of primary cell cultures and in the analysis of gene expression patterns. After completing her academic education, she continued her research activity in the field of pharmaceutical technologies, working on the preparation of polymeric systems for the controlled release of drugs as well as on development and validation of analytical methods, with a specific focus on the accreditation of testing laboratories as well as certification of quality management systems. She is author or co-author of 10 international papers and 2 patents about innovative pharmaceutical formulations.


Chief Executive Officier (CEO), Chief Scientific Officer & Founder

Lisa Elviri, professor of Analytical chemistry at the University of Parma, is Chief Executive Officer and Chief Scientific Officer at M3DATEK Srl. Since 2001 she is a researcher at the University of Parma gaining a sound experience in the management of analytical laboratories and research and development programs. Strongly believing in inter-disciplinary formation, she worked in the biotech, food, forensic, environmental and clinical fields as project manager and developer of immunoassay nanotechnology printing-based diagnostic kits for private companies (UK, D), focusing attention to the scientific and technological transfer. Her research experience includes preparation and characterization of polymeric materials, proteins of biological and food interest, method development and validation, mass spectrometry, immunoassay and chemiometry. She is Author of 80 international publications, one patent and more than 140 partecipations to national and international congress.


Biopharmaceutical Project Manager (PM) & co-Founder

Carlo Bergonzi, graduated in Health Biotechnology, developed expertise in the biochemistry and molecular Biology field during his bachelor degree internship in “Biological sciences”. Further competences in the Biotech and Pharmaceutical technology field have been acquired during the master degree internship period and subsequently to a period of one year of scolarship at the interdepartmental center for the innovation of health products Biopharmanet-tec. He’s a candidate PhD in “Scienze del Farmaco, delle Biomolecole e dei Prodotti per la Salute” at the University of Parma, dedicating himself to the development of the 3D printing technology apllication in biomedicine and and tissue regeneration. He is co-author of 2 international papers about innovative pharmaceutical formulations and analytical technique validation in mass spectrometry


Senior Advisor & co-Founder

Ruggero Bettini is full professor of Pharmaceutical technology at the Department of Pharmacy of the University of Parma and Senior Advisor ad M3DATEK Srl. Already founder of the start-up PlumeStars srl, his professional experience is focused on the technological transfer between University and private Pharma-companies, mainly on the preparation of solid dosage forms for controlled and site-specific drug delivery, as well as solid-state chemistry for improving biopharmaceutical properties of active pharmaceutical ingredients, in particular with natural polymers for regenerative medicine applications. He is Author or co-author of 95 international papers and 15 patents.